ANXA8L2 antibody - middle region (ARP36574_P050)
- Known as:
- ANXA8L2 (anti-) - middle region (ARP36574_P050)
- Catalog number:
- arp36574_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- ANXA8L2 antibody - middle region (ARP36574_P050)
Related genes to: ANXA8L2 antibody - middle region (ARP36574_P050)
- Gene:
- ANXA8L1 NIH gene
- Name:
- annexin A8 like 1
- Previous symbol:
- ANXA8L2
- Synonyms:
- bA301J7.3, bA145E20.2
- Chromosome:
- 10q11.22
- Locus Type:
- gene with protein product
- Date approved:
- 2004-06-02
- Date modifiied:
- 2017-02-20
Related products to: ANXA8L2 antibody - middle region (ARP36574_P050)
Related articles to: ANXA8L2 antibody - middle region (ARP36574_P050)
- Breast cancer (BRCA) is the most common cancer in women worldwide, yet current gene expression panels offer limited insight into treatment responses across different subtypes and therapies. This study aimed to identify reliable biomarkers for predicting treatment outcomes in specific BRCA subtypes and treatment regimens. - Source: PubMed
Publication date: 2026/09/09
Pitinanon KrittinKusalasaiyanon ChotiphukHawhan WathunyaLiu Yu-YuTaechawattananant PasrawinYodsurang Varalee - Partial epithelial-mesenchymal transition (p-EMT) is a dynamic cellular state associated with metastasis and adverse outcomes in multiple cancers, but its prognostic significance in ovarian cancer remains unclear. This study aimed to develop and validate an ovarian cancer-specific transcriptomic signature based on p-EMT-related genes, and to determine whether this signature can improve prognostic stratification and overall survival prediction across independent cohorts. - Source: PubMed
Publication date: 2026/04/22
Chao Chia-ChiaLin Cheng-YaoChen Po-ChunHuang Wen-TsungWeng Teng-SongHsiao Sheng-Yen - Annexins are a family of proteins involved in a wide variety of cellular processes such as inflammation, proliferation, differentiation, apoptosis, migration and membrane repair. However, the role of most Annexins in renal cell carcinoma (RCC) remained unclear. - Source: PubMed
Publication date: 2023/07/18
Wang Li-HuiCao BoLi Yun-LongQiao Bao-Ping - (1) Background: Non-small cell lung cancer (NSCLC) is the most common lung cancer. Enhancer RNA (eRNA) has potential utility in the diagnosis, prognosis and treatment of cancer, but the role of eRNAs in NSCLC metastasis is not clear; (2) Methods: Differentially expressed transcription factors (DETFs), enhancer RNAs (DEEs), and target genes (DETGs) between primary NSCLC and metastatic NSCLC were identified. Prognostic DEEs (PDEEs) were screened by Cox regression analyses and a predicting model for metastatic NSCLC was constructed. We identified DEE interactions with DETFs, DETGs, reverse phase protein arrays (RPPA) protein chips, immunocytes, and pathways to construct a regulation network using Pearson correlation. Finally, the mechanisms and clinical significance were explained using multi-dimensional validation unambiguously; (3) Results: A total of 255 DEEs were identified, and 24 PDEEs were selected into the multivariate Cox regression model (AUC = 0.699). Additionally, the NSCLC metastasis-specific regulation network was constructed, and six key PDEEs were defined (ANXA8L1, CASTOR2, CYP4B1, GTF2H2C, PSMF1 and TNS4); (4) Conclusions: This study focused on the exploration of the prognostic value of eRNAs in the metastasis of NSCLC. Finally, six eRNAs were identified as potential markers for the prediction of metastasis of NSCLC. - Source: PubMed
Publication date: 2022/06/26
Liu JunJia JingyiWang SiqiaoZhang JunfangXian ShuyuanZheng ZixuanDeng LinFeng YonghongZhang YuanZhang Jie - To reconstruct the ceRNA biological network of cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) and to select an appropriate mRNA as a biomarker that could be used for CESC early diagnosis and prognosis evaluation. We downloaded CESC data from the TCGA public database, and statistical analysis was conducted with the R software to find out differential expressed genes encoding for lncRNAs, miRNAs, and mRNAs. The differentially expressed mRNAs (DEmRNAs) screened in the ceRNA network were analyzed for survival to find the mRNAs with significantly linked to the survival prognosis. These mRNAs were searched in the Pathological Atlas to identify the final appropriate mRNAs. Differential expression analysis revealed 773 lncRNAs, 94 miRNAs, and 2466 mRNAs. Survival analysis of DEmRNAs in the ceRNA network indicated that ADGRF4, ANXA8L1, HCAR3, IRF6, and PDE2A ( < 0.05) were negatively correlated with survival time. Verification of these six DEmRNAs in the Pathology Atlas indicated that PDE2A was a possible biomarker for CESC patients. PDE2A might be a biomarker for early diagnosis and prognosis evaluation of CESC patients, but due to the lack of available data, further studies may be needed for confirmation. - Source: PubMed
Publication date: 2020/04/12
Ding HaoXiong Xiao-XingFan Guan-LanYi Yue-XiongChen Yu-RouWang Jing-TaoZhang Wei